673 related articles for article (PubMed ID: 23551194)
1. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.
Lindeman NI; Cagle PT; Beasley MB; Chitale DA; Dacic S; Giaccone G; Jenkins RB; Kwiatkowski DJ; Saldivar JS; Squire J; Thunnissen E; Ladanyi M
Arch Pathol Lab Med; 2013 Jun; 137(6):828-60. PubMed ID: 23551194
[TBL] [Abstract][Full Text] [Related]
2. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.
Lindeman NI; Cagle PT; Beasley MB; Chitale DA; Dacic S; Giaccone G; Jenkins RB; Kwiatkowski DJ; Saldivar JS; Squire J; Thunnissen E; Ladanyi M
J Thorac Oncol; 2013 Jul; 8(7):823-59. PubMed ID: 23552377
[TBL] [Abstract][Full Text] [Related]
3. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.
Lindeman NI; Cagle PT; Beasley MB; Chitale DA; Dacic S; Giaccone G; Jenkins RB; Kwiatkowski DJ; Saldivar JS; Squire J; Thunnissen E; Ladanyi M; College of American Pathologists International Association for the Study of Lung Cancer and Association for Molecular Pathology
J Mol Diagn; 2013 Jul; 15(4):415-53. PubMed ID: 23562183
[TBL] [Abstract][Full Text] [Related]
4. Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.
Lindeman NI; Cagle PT; Aisner DL; Arcila ME; Beasley MB; Bernicker EH; Colasacco C; Dacic S; Hirsch FR; Kerr K; Kwiatkowski DJ; Ladanyi M; Nowak JA; Sholl L; Temple-Smolkin R; Solomon B; Souter LH; Thunnissen E; Tsao MS; Ventura CB; Wynes MW; Yatabe Y
J Mol Diagn; 2018 Mar; 20(2):129-159. PubMed ID: 29398453
[TBL] [Abstract][Full Text] [Related]
5. Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the study of lung cancer/association for molecular pathology guideline.
Leighl NB; Rekhtman N; Biermann WA; Huang J; Mino-Kenudson M; Ramalingam SS; West H; Whitlock S; Somerfield MR
J Clin Oncol; 2014 Nov; 32(32):3673-9. PubMed ID: 25311215
[TBL] [Abstract][Full Text] [Related]
6. Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.
Lindeman NI; Cagle PT; Aisner DL; Arcila ME; Beasley MB; Bernicker EH; Colasacco C; Dacic S; Hirsch FR; Kerr K; Kwiatkowski DJ; Ladanyi M; Nowak JA; Sholl L; Temple-Smolkin R; Solomon B; Souter LH; Thunnissen E; Tsao MS; Ventura CB; Wynes MW; Yatabe Y
Arch Pathol Lab Med; 2018 Mar; 142(3):321-346. PubMed ID: 29355391
[TBL] [Abstract][Full Text] [Related]
7. Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update.
Kalemkerian GP; Narula N; Kennedy EB; Biermann WA; Donington J; Leighl NB; Lew M; Pantelas J; Ramalingam SS; Reck M; Saqi A; Simoff M; Singh N; Sundaram B
J Clin Oncol; 2018 Mar; 36(9):911-919. PubMed ID: 29401004
[TBL] [Abstract][Full Text] [Related]
8. Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(24):1-48. PubMed ID: 23074402
[TBL] [Abstract][Full Text] [Related]
9. Developments for Personalized Medicine of Lung Cancer Subtypes: Mass Spectrometry-Based Clinical Proteogenomic Analysis of Oncogenic Mutations.
Nishimura T; Nakamura H
Adv Exp Med Biol; 2016; 926():115-137. PubMed ID: 27686809
[TBL] [Abstract][Full Text] [Related]
10. Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.
Lindeman NI; Cagle PT; Aisner DL; Arcila ME; Beasley MB; Bernicker EH; Colasacco C; Dacic S; Hirsch FR; Kerr K; Kwiatkowski DJ; Ladanyi M; Nowak JA; Sholl L; Temple-Smolkin R; Solomon B; Souter LH; Thunnissen E; Tsao MS; Ventura CB; Wynes MW; Yatabe Y
J Thorac Oncol; 2018 Mar; 13(3):323-358. PubMed ID: 29396253
[TBL] [Abstract][Full Text] [Related]
11. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
12. Management and future directions in non-small cell lung cancer with known activating mutations.
Gerber DE; Gandhi L; Costa DB
Am Soc Clin Oncol Educ Book; 2014; ():e353-65. PubMed ID: 24857124
[TBL] [Abstract][Full Text] [Related]
13. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
[TBL] [Abstract][Full Text] [Related]
14. Present and future molecular testing of lung carcinoma.
Dacic S; Nikiforova MN
Adv Anat Pathol; 2014 Mar; 21(2):94-9. PubMed ID: 24508692
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of resistance to EGFR tyrosine kinase inhibitors gefitinib/erlotinib and to ALK inhibitor crizotinib.
Tartarone A; Lazzari C; Lerose R; Conteduca V; Improta G; Zupa A; Bulotta A; Aieta M; Gregorc V
Lung Cancer; 2013 Sep; 81(3):328-336. PubMed ID: 23809060
[TBL] [Abstract][Full Text] [Related]
16. Biopsy Procedures and Molecular Testing Utilization and Related Costs in Patients with Metastatic Lung Cancer.
Shinde R; Cao X; Kothari S
J Manag Care Spec Pharm; 2016 Oct; 22(10):1194-203. PubMed ID: 27668568
[TBL] [Abstract][Full Text] [Related]
17. Clinical Management of Non-Small Cell Lung Cancer with Concomitant EGFR Mutations and ALK Rearrangements: Efficacy of EGFR Tyrosine Kinase Inhibitors and Crizotinib.
Zhao Y; Wang S; Zhang B; Qiao R; Xu J; Zhang L; Zhang Y; Han B
Target Oncol; 2019 Apr; 14(2):169-178. PubMed ID: 30888598
[TBL] [Abstract][Full Text] [Related]
18. Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report.
Rossing HH; Grauslund M; Urbanska EM; Melchior LC; Rask CK; Costa JC; Skov BG; Sørensen JB; Santoni-Rugiu E
BMC Res Notes; 2013 Nov; 6():489. PubMed ID: 24279718
[TBL] [Abstract][Full Text] [Related]
19. Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology.
Gridelli C; de Marinis F; Cappuzzo F; Di Maio M; Hirsch FR; Mok T; Morgillo F; Rosell R; Spigel DR; Yang JC; Ciardiello F
Clin Lung Cancer; 2014 May; 15(3):173-81. PubMed ID: 24486058
[TBL] [Abstract][Full Text] [Related]
20. Personalized targeted therapy for lung cancer.
Wu K; House L; Liu W; Cho WCS
Int J Mol Sci; 2012; 13(9):11471-11496. PubMed ID: 23109866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]